Julie Brush, Solutus founding partner. Once upon a time, there was a lawyer. She was a solid lawyer: Heads down, hard worker and always ready to solve the next legal issue with precision and ...

Acumen Pharmaceuticals is developing an Alzheimer’s disease drug that it believes offers advantages compared to other approaches—including the recently approved Biogen therapy. A small clinical trial ...

Strategic thinking involves seeing the big picture of your business and the specific paths to its growth amid changing consumer trends and competition. Having business acumen means understanding all ...

Acumen Pharmaceuticals is showing it has the business acumen to bring forward its Alzheimer's disease drug candidate. Investors seem to have taken stock of this on the company's first day of trading.

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Acumen Pharmaceuticals has set the terms for its IPO, teeing it up to raise around $125 million to take an antibody against amyloid-beta oligomers to the end of phase 2 in Alzheimer’s disease.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

If leadership is devoid of strategic acumen then the country can never be stable, prosperous and strong. Strategic acumen is a major requirement for a country like Pakistan which has passed through ...

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026 Cash, cash equivalents and marketable ...

A few years ago, Acumen, the pioneering patient capital impact investment firm, developed a unique method for measuring impact called Lean Data. Now, it’s spinning off that approach into a separate ...

CEO Daniel O'Connell stated that "in the third quarter, we continued our track record of operational execution on 2 fronts: the steady progression of our Phase II ALTITUDE-AD trial and the generation ...

BLUE BELL, Pa., May 13, 2021 /PRNewswire-PRWeb/ — Acumen Health HoldingsTM is proud to announce that it has acquired Ramard, Inc. into its portfolio of leading health product companies in order to ...